Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor—the End or Beginning?
نویسندگان
چکیده
منابع مشابه
Rehabilitation of Schizophrenia: At the End or in the Beginning?
The Majority of the long stay psychiatric patients who are in need of rehabilitation suffer from schizophrenia. Most of them enter the old age with this illness, and besides the consequences of schizophrenia, they are facing the deprivation and misery due to the old age. In contrast to the previous decades in which there was no effective treatment for schizophrenia, today with the immediate dia...
متن کاملStreptokinase for Treatment of Thrombotic Disorders: The End? Or the End of the Beginning?
Thrombotic disorders, such as myocardial infarction, ischemic stroke, peripheral arterial disease, deep venous thrombosis, pulmonary embolism, or other embolic diseases that are responsible for worldwide mortality and morbidity, are manifestations of the formed thrombi by blood clots during a pathologic blood coagulation process. Once thrombi are formed, the only way to resolve the blood clot i...
متن کاملCardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
BACKGROUND Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approved by both US and European Commission regulatory agencies for clinical use, extends survival of patients with metastatic renal-cell carcinoma and gastrointestinal stromal tumours, but concerns have arisen about its cardiac safety. We therefore assessed the cardiovascular risk associated with sunitinib in patients wi...
متن کاملVocational training: the end or the beginning?
performance and consultation skill work. The trial GPs improved their detection rate significantly, both compared to their performance at baseline and compared to the control group. Everyday consulting requires GPs to switch their attention quickly from perhaps an elderly arthritic patient, a patient with diabetes, a feverish child, and someone with headache, backache or persistent tiredness wh...
متن کاملTyrosine kinase inhibitor-induced macrocytosis.
BACKGROUND The tyrosine kinase inhibitors (TKI) sunitinib and imatinib were shown to induce macrocytosis in patients with renal cell cancer (RCC) and gastrointestinal stromal tumors (GIST), presumably through inhibition of the c-KIT dependent signaling pathway of erythroid progenitor cells of the bone marrow. PATIENTS AND METHODS Hematology charts of patients with RCC, breast cancer (BC), GIS...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2020
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2019.12.121